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ABSTRACT
1.7 million cases of breast cancer are diagnosed every year with 522,000 deaths.   
Molecular classifications of breast cancer have resulted in improved treatments. 
However, treatments for triple negative breast cancer (TNBC) are lacking.  Analysis of 
molecular targets for TNBC is a priority. One potential candidate is androgen receptor 
(AR) phosphorylation.  This study assessed the role of AR phosphorylation at ser81/
ser515 and their two upstream effectors, cyclin-dependent kinase 1 (pCDK1) and 
extracellular-regulated kinase 1/2 (pERK1/2) in 332 ductal breast cancer patients 
by immunohistochemistry.  
pERK1/2 combined with AR-515 associated with improved cancer-specific survival 
(CSS, p = 0.038), decreased size (p = 0.001), invasive grade (p < 0.001), necrosis  
(p = 0.003), b-lymphocytes (p = 0.020), molecular subtype (p < 0.001) and estrogen 
receptor (ER)/progesterone receptor (PR)-status (p < 0.001).  The cohort was therefore 
stratified into ER+ve and ER-ve patients.  In ER+ve tumours, pERK1/2 combined with 
AR-515 associated with improved CSS (p = 0.038), smaller size (p = 0.004), invasive 
grade (p = 0.001), decreased b-lymphocytes (p = 0.013) and increased plasma cells 
(p = 0.048).  In contrast, in TNBC patients, phosphorylation of AR-515 associated with 
poorer CSS (p = 0.007). pERK1/2 combined with AR-515 associated with decreased 
inflammation (p = 0.003), increased tumour stroma (p = 0.003) and tumour budding 
(p = 0.011), with trends towards decrease CSS (p = 0.065) and macrophage levels  
(p = 0.093).
In Conclusions, AR-515 may be an important regulator of inflammation in breast 
cancer potential via ERK1/2 phosphorylation.  AR-515 is a potential prognostic marker 
and therapeutic target for TNBC.
INTRODUCTION
Approximately 1.7 million cases of breast cancer are 
diagnosed every year. About 522,000 die of breast cancer 
yearly making it the 5th most common cause of cancer 
death globally [1]. A great effort is being channelled to 
improve the understanding of the pathogenesis of this 
disease as breast cancer is highly heterogeneous with 
an increasing number of sub-classifications being made 
[2–4]. In the past 2 decades, 4 molecular classifications of 
breast cancer have been extensively studied (Luminal A, 
Luminal B, HER2-type and Triple negative breast cancer 
(TNBC)) that have resulted in improved treatments [5, 6]. 
The majority of breast cancers comprise of luminal A 
and luminal B subtypes. These subtypes display oestrogen 
(ER) and/or progesterone receptors (PR) rendering these 
cancer cells susceptible to endocrine therapies e.g. anti-
oestrogen therapies (Tamoxifen) [7, 8]. In HER2 positive 
breast cancer, the presence of HER2, a tyrosine kinase 
receptor that is part of the EGFR family, enables targeted 
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therapeutics (Trastuzumab, Pertuzumab) to be effective 
[9, 10]. However, about 15% of breast cancer cases are 
triple receptor negative lacking expression of ER, PR or 
HER2 [11]. 
It has been shown that TNBC patients displaying 
pathological complete response (pCR) had better 
outcomes in terms of progression-free survival than 
patients who had not achieved pCR [12]. pCR is defined 
as an absence of any residual invasive breast cancer in 
the breast and axillary lymph nodes upon completion of 
chemotherapy [13]. Hence, there is an increasing need 
for targeted therapies to achieve pCR for TNBC cases. 
Current pathways that are being studied for this purpose 
include EGFR, aB-crystallin and androgen receptors (AR) 
[14–16].
Although numerous studies on AR have been 
published, the exact role of AR as tumour-promoting 
or anti-tumorigenic remains undecided. It is known 
that AR signalling plays a role in regulating cancer cell 
proliferation and apoptosis [17–19]. AR activation by the 
binding of androgens such as DHT to AR displaces HSP90 
(heat shock protein 90), a chaperone protein to allow the 
dimerization of AR. The DHT–AR dimer complex then 
translocates to the nucleus to trigger the activation of the 
genetic machinery, stimulating cell proliferation. During 
this process, post-translational modifications such as 
phosphorylation are triggered at multiple sites within AR. 
It is now thought that it is these phosphorylation events 
that fully activate the AR and modulate its different 
cellular functions [20]. 
It was also reported that when Tamoxifen-resistant 
breast cancer cells that expressed high levels of AR were 
exposed to bicalutamide (anti-androgen), cell growth 
was shown to decrease as well as reversing Tamoxifen 
resistance [21], indicating that AR expression may be a 
mechanism of breast cancer cell adaptation to stimulate 
cell proliferation in an anti-oestrogen environment. A 
study by Ayca Gucalp et al. observed that bicalutamide in 
ER negative and AR positive breast cancer demonstrated 
improved progression-free survival [22], lending further 
support that AR or its signalling pathways may be a 
tangible route for treating patients in the ER negative 
subgroup. 
The MAPK/ERK signalling cascade is heavily 
involved in the regulation of cancer cell proliferation, 
growth and differentiation. The stimulation of this pathway 
leads to the activation of a cascade of kinases (e.g. Ras, Raf, 
MEK), which ultimately leads to the activation of ERK1/2, 
which is associated with poor prognosis in breast cancer 
[23]. One function of ERK1/2 is to phosphorylate AR on 
ser-515. This is an example of ligand-independent activation 
via phosphorylation of AR, which is thought to be one of the 
main mechanisms of AR activation in cancer [24]. 
In contrast, AR phosphorylation at ser-81 is the 
prototypical site for dihydrotestosterone (DHT) activation, 
which is thought to be facilitated by activated Cdk1, as 
observed by Chen et al where Cdk1 inhibitors decreased 
ser-81 phosphorylation of AR in LNCaP cells and similarly 
decreased AR protein expression and transcriptional 
activity. Whereas transfected Cdk1 stimulated AR 
phosphorylation at ser-81 and increased AR protein 
expression [25]. This suggestion has been supported by 
another study by Yulia et al where in vitro kinase assays 
demonstrated an increase in ser-308 phosphorylation by 
CDK1 is responsible for Serine–81 phosphorylation [20]. 
Cdk1 phosphorylation of AR-81 has also been associated 
with decreased survival in prostate cancer patients [26].  
This study aims to further understand the role 
of androgens and AR activation in breast cancer by 
determining its effect on patient survival. This is followed 
by the determination of the role of upstream pathways 
(i.e. Cdk1 and ERK1/2 pathways) on AR activation and 
their effects on cancer specific survival (CSS). We aim 
to confirm that the phosphorylation of AR at either ser-
515 or ser-81 is a surrogate for AR activation and assess 
if the pathways responsible for this phosphorylation are 
potential targets for therapeutic intervention. 
RESULTS
Phosphorylation of AR-515 associates with 
improved cancer-specific survival in ductal 
breast cancer patients
Only patients with staining for AR, AR-81 and AR-
515 were included in the analysis (n = 332, Figure 1A). 
The majority of the patients (71%) were above 50 years 
old, had small tumour size ≤ 20 mm (58%), had grade 
II and III tumours (80%) and no involved lymph nodes 
(53%). ER positive tumours (69%), PR negative tumours 
(52%) and HER2 negative tumours (82%) formed the 
majority of tumours, with 20% of cases being triple 
negative. Overall, 119 (36%) had lumpectomy and 
radiotherapy, and 213 (64%) had mastectomy and 
radiotherapy. 176 (53%) of the patients received endocrine 
therapy alone, 62 (19%) of patients received adjuvant 
chemotherapy only, while 76 (23%) had both.  The median 
survival was 148 months with 69 deaths from breast 
cancer and 68 deaths from non-cancer related causes.
The relationship between nuclear AR activation 
and CSS is shown in Table 1. Only nuclear expression 
was investigated as this represents the active form of 
the protein. High levels of nuclear AR activation via 
phosphorylation of serine 81 (AR-81) or serine 515 
(AR-515) were identified in 155 (47%) and 167 (50%) 
patients, respectively.  Neither AR-81 (p = 0.842) nor 
AR-515 (p = 0.563) were associated with CSS alone. 
Therefore, upstream effectors of AR phosphorylation 
were investigated.  AR-81 significantly correlated with 
nuclear CDK1 (p < 0.001) and AR-515 correlated with 
nuclear pERK1/2 (p < 0.001) as expected.  However, AR-
81 still showed no associations even when combined with 
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CDK1 in the nucleus (p = 0.344). In contrast, AR-515 
was significantly associated with improved CSS when 
combined with ERK1/2 phosphorylation in the nucleus 
(pERK1/2, p = 0.032). When nuclear pERK1/2 was 
assessed alone it was also significantly associated with 
improved CSS (p = 0.004).  Therefore, further analysis 
was confined to nuclear pERK1/2 and AR-515.
The relationship between pERK1/2, AR-515, 
clinicopathological characteristics, and local inflammatory 
response is presented in Table 2. pERK1/2 was 
significantly associated with smaller size (p = 0.001), 
lower grade (p < 0.001), ER/PR+ve tumours (p < 0.001), 
molecular subtype (p < 0.001), lower necrosis (p = 0.003), 
weak Klintrup-Makinen (KM) grade (p = 0.004) and 
lower b-lymphocyte levels (p = 0.020).  There was also 
a trend towards decreased HER2 (p = 0.096) and lower 
lymphovascular invasion (p = 0.099).  When pERK1/2 
was combined with AR-515 significant associations 
were still seen with smaller size (p = 0.017), lower grade 
(p < 0.001), ER+ve tumours (p = 0.013), PR+ve tumours 
(p = 0.008), decreased HER2 (p = 0.041), molecular 
subtype (p < 0.001), lower necrosis (p = 0.006), weak KM 
grade (p = 0.005) and lower b-lymphocytes (p = 0.023). 
Significant associations were now also seen with decreased 
proliferation (p = 0.009), lymphovascular invasion 
(p = 0.017) and increased tumour budding (p = 0.047).
AR-515 associates with improved cancer-specific 
survival in ER+ve breast cancer patients
As pERK1/2 plus AR-515 associated with molecular 
subtype, we firstly stratified patients into ER+ve and ER-
ve tumours (Supplementary Table 1).  pERK1/2 was 
associated with improved CSS only in ER+ve tumours 
Table 1: Relationship between ligand-independent AR phosphorylation and cancer-specific 
survival in patients with invasive ductal breast cancer (n = 332) 
N (%) 10yr-CSS %
(SE)
Univariate HR
(95% CI)
P
Total AR expression
 Low expression
 High expression
167 (50)
165 (50)
79 (3)
80 (3)
1.04 (0.65–1.67) 0.869
AR-81 phosphorylation
 Low expression
 High expression
177 (53)
 155 (47)
79 (3)
78 (4)
0.95 (0.59–1.53) 0.842
AR-515 phosphorylation
 Low expression
 High expression
165 (50)
167 (50)
78 (3)
79 (3)
0.87 (0.54–1.40) 0.563
CDK1 phosphorylation (n = 227)
 Low expression
 High expression
118 (52)
109 (48)
76 (4)
77 (4)
1.00 (0.57–1.74) 0.985
ERK1/2 phosphorylation
 Low expression
 High expression 
151 (45)
181 (55)
72 (4)
84 (3)
0.49 (0.30–0.80) 0.004
Combined AR + AR-81
 Low AR + AR-81
 High AR or AR-81
 High AR + AR-81
91 (27)
162 (49)
79 (24)
80 (4)
77 (3)
79 (5)
1.00 (0.72–1.39) 0.851
Combined AR + AR-515
 Low AR + AR-515
 High AR or AR-515
 High AR + AR-515
95 (29)
142 (42)
95 (29)
78 (4)
79 (4)
79 (5)
0.96 (0.70–1.31) 0.903
Combined pCDK1 + AR-81 (n = 227)
 Low pCDK1 + AR-81
 High pCDK1 or AR-81
 High pCDK1 + AR-81
68 (30)
101 (44)
58 (26)
78 (6)
72 (5)
83 (5)
0.88 (0.60–1.28) 0.344
Combined pERK1/2 + AR-515
 Low pERK + AR-515
 High pERK or AR-515
 High pERK + AR-515
94 (28)
128 (39)
110 (33)
77 (5)
73 (4)
88 (3)
0.72 (0.53–0.98) 0.032
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Table 2: Relationship between clinico-pathological characteristics and ERK1/2 plus AR-515 in 
patients with invasive ductal breast cancer (n = 332)
pERK1/2 pERK1/2 + AR-515
Low  
(n = 150)
High 
(n = 181) P
Low pERK + AR-
515 (n = 93)
High pERK 
or AR-515
(n = 128)
High pERK 
+ AR-515
(n = 110)
P
Clinicopathological 
Characteristics
Age
 ≤ 50 years
 > 50 years
46 (31)
104 (69)
50 (28)
131 (72)
0.544
29 (31)
64 (69)
32 (25)
96 (75)
35 (31)
75 (69)
0.442
Size
 ≤ 20 mm
 21–50 mm
 > 50 mm
74 (49)
68 (45)
8 (6)
117 (65)
63 (34)
1 (1)
0.001
46 (49)
44 (47)
3 (4)
73 (57)
50 (39)
5 (4)
72 (65)
37 (34)
1 (1)
0.017
Invasive Grade
 I
 II
 III
14 (9)
57 (38)
79 (53)
51 (28)
84 (46)
46 (26)
< 0.001
10 (10)
35 (38)
48 (52)
20 (16)
64 (50)
44 (34)
35 (32)
42 (38)
33 (30)
< 0.001
Lymph Node Involvement
 No
 Yes
81 (54)
69 (46)
96 (53)
85 (47)
0.874
53 (57)
40 (43)
63 (49)
65 (51)
60 (55)
50 (45)
0.779
ER Status
 No
 Yes
68 (45)
82 (55)
35 (19)
146 (81)
< 0.001
35 (38)
58 (62)
44 (34)
84 (66)
24 (22)
86 (88)
0.013
PR status
 No
 Yes
94 (63)
56 (37)
76 (42)
105 (58)
< 0.001
55 (59)
38 (41)
70 (55)
58 (45)
45 (41)
65 (59)
0.008
Her2 status
 No
 Yes
120 (80)
30 (20)
157 (87)
24 (13)
0.096
74 (80)
19 (20)
104 (81)
24 (19)
99 (90)
11 (10)
0.041
Molecular Subtype
 Luminal A
 Luminal B
 TNBC
 Her2+
49 (33)
36 (24)
44 (29)
21 (14)
108 (60)
41 (23)
23 (13)
9 (4)
<  0.001
30 (32)
32 (34)
21 (23)
10 (11)
61 (48)
24 (19)
27 (21)
16 (13)
67 (61)
22 (20)
18 (16)
3 (3)
< 0.001
Tumour Necrosis
 Low
 High
61 (41)
89 (59)
103 (57)
78 (43)
0.003
40 (43)
53 (57)
56 (44)
72 (56)
68 (62)
42 (38)
0.006
Ki67 proliferation index
 Low
 High
107 (71)
43 (29)
140 (77)
41 (23)
0.177
59 (63)
34 (37)
100 (78)
28 (22)
88 (80)
22 (20)
0.009
Lymphatic Invasion
 No
 Yes
99 (66)
51 (34)
119 (66)
62 (34)
0.961
64 (69)
29 (31)
80 (62)
48 (38)
74 (67)
36 (33)
0.859
Lymphovascular Invasion
 No
 Yes
127 (85)
23 (15)
164 (91)
17 (9)
0.099
76 (82)
17 (18)
113 (88)
15 (12)
102 (93)
8 (7)
0.017
Inflammatory Infiltrate
Klintrup Makinen Grade
 Weak
 Strong
103 (69)
47 (31)
149 (82)
32 (18)
0.004
64 (69)
29 (31)
94 (73)
34 (27)
94 (85)
16 (15)
0.005
CD68+ macrophages
 Low
 Moderate
 High
31 (21)
53 (35)
66 (44)
32 (17)
79 (44)
70 (39)
0.776
13 (14)
38 (41)
42 (45)
31 (24)
42 (33)
55 (47)
19 (17)
52 (47)
39 (36)
0.228
CD4+ T-lymphocytes
 Low
 Moderate
 High
54 (36)
37 (25)
59 (39)
82 (45)
36 (20)
63 (35)
0.156
33 (35)
28 (30)
32 (35)
54 (42)
21 (16)
53 (41)
49 (44)
24 (22)
37 (34)
0.413
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(p = 0.008). As pERK1/2 and AR-515 strongly correlated 
in ER+ve patients (p < 0.001) they were combined. 
However, when combined the survival effect was 
weakened (p = 0.038), suggesting that pERK can also 
act independently of AR-515 in ER+ve breast cancers. 
When ER+ve patients where stratified further, there was 
no difference in CSS between luminal A and luminal B 
subtypes for pERK1/2 alone or combined with AR-515 
therefore further analysis was carried out in all ER+ve 
tumours (n = 228).  
The relationship between pERK1/2, AR-515, 
clinicopathological characteristics, and local inflammatory 
response in ER+ve tumours is presented in Table 3. 
pERK1/2 was significantly associated with smaller size 
(p = 0.004), lower grade (p = 0.001), molecular subtype 
(p = 0.024), decreased proliferation (p = 0.006), lower 
b-lymphocytes (p = 0.013) and increased plasma cells 
 (p = 0.048).  There was also a trend towards decreased 
necrosis (p = 0.096).  When pERK1/2 was combined 
with AR-515 significant associations where still seen 
with lower grade (p = 0.002), molecular subtype 
(p = 0.001), decreased proliferation (p = 0.001), lower 
b-lymphocytes (p = 0.006) and increased plasma cells 
(p = 0.023).  Significant associations were now also seen 
with decreased necrosis (p = 0.009) and lymphovascular 
invasion (p = 0.029).  
AR phosphorylation at Ser515 associates with 
poorer patient survival in TNBC
It was observed in patients with ER-ve breast 
cancer that high pERK1/2 plus AR-515 had a trend 
towards an effect on survival rate.  It was hypothesised 
that the loss of significance and weaker correlation 
between pERK1/2 and AR-515 in ER-ve patients 
(p = 0.023) may be due to differences between the two 
ER-ve subtypes.  Therefore, ER-ve patients were stratified 
into HER2-type and TNBC to further investigate these 
effects (Supplementary Table 2).  In patients with TNBC, 
the correlation between pERK1/2 and AR-515 was 
strengthened (p = 0.010), however no significant effect 
on CSS was observed for pERK1/2 alone (p = 0.534) 
and only a trend towards poorer outcome was seen when 
combined with AR-515 (p = 0.065).  However, high 
levels of AR-515 combined with total AR, representing 
full AR activation, associated with a significantly poorer 
outcome (p = 0.007, Figure 1A), and a similar effect was 
also seen when total AR was considered alone (p = 0.006, 
Figure 1B).  In contrast, in patients with HER2-type cancers 
the correlation between pERK1/2 and AR-515 was lost 
(p = 0.949) and no significant associations were seen 
in these patients.  However, there was a trend towards 
improved patient survival with AR-515 phosphorylation 
(p = 0.056) alone and when combined with pERK1/2 
(p = 0.076), confirming our hypothesis that these 
two ER-ve subtypes respond differently to AR-515 
phosphorylation.
Due to the detrimental effect of AR-515 phosphorylation 
in TNBC, associations with clinicopathological characteristics 
were assessed (Table 4).  Full activation of the AR receptor 
as shown by AR-515 plus total AR significantly associated 
with increased lymphovascular invasion (p = 0.033), lower 
KM grade (p = 0.004), increased tumour-stroma percentage 
(TSP) (p = 0.033) and increased tumour budding (p = 0.007). 
When combined with pERK1/2 associations were still seen 
with lower KM grade (p = 0.003), increased TSP (p = 0.003) 
and increased tumour budding (p = 0.011).  Trends towards 
association were also seen for increased age (p = 0.075) and 
decreased macrophages (p = 0.093).
CD8+ cytotoxic T-cells
 Low
 Moderate
 High
39 (26)
54 (36)
57 (38)
51 (28)
69 (38)
61 (34)
0.458
24 (25)
35(38)
34 (37)
33 (26)
47 (37)
48 (37)
33 (30)
41 (37)
36 (33)
0.452
CD20+ B-lymphocytes
 Low
 Moderate
 High
65 (43)
24 (16)
61 (41)
100 (55)
28 (15)
53 (30)
0.020
42(45)
12 (13)
39 (42)
58 (45)
25 (20)
45 (35)
65 (59)
15 (14)
30 (27)
0.023
CD138+ plasma cells
 Low
 Moderate
 High
78 (52)
19 (13)
53 (35)
78 (43)
33 (18)
70 (39)
0.225
51 (55)
13 (14)
29 (31)
60 (47)
16 (13)
52 (40)
45 (41)
23 (21)
42 (38)
0.111
Tumour Stroma Percentage
 Low
 High
100 (66)
50 (34)
117 (65)
64 (35)
0.700
64 (69)
29 (31)
88 (69)
40 (31)
65 (59)
45 (41)
0.134
Tumour Budding
 Low
 High
97 (65)
53 (35)
111 (61)
70 (39)
0.532
65 (70)
28 (30)
81 (63)
47 (37)
62 (56)
48 (44)
0.047
Angiogenesis (n = 321)
 Low
 Moderate
 High
46 (31)
46 (31)
55 (38)
55 (31)
62 (36)
57 (33)
0.586
29 (32)
28 (31)
34 (37)
46 (36)
40 (32)
40 (32)
26 (25)
40 (38)
38 (37)
0.564
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Table 3: Relationship between clinico-pathological characteristics and AR-515 in patients with 
ER + ve invasive ductal breast cancer (n = 228)
pERK1/2 pERK1/2 + AR-515
Low  
(n = 82)
High 
(n = 146) P
Low pERK + 
AR-515
(n = 58)
High pERK or 
AR-515
 (n = 84)
High pERK 
+ AR-515
(n = 86)
P
Clinicopathological 
Characteristics
Age
 ≤ 50 years
 > 50 years
18 (22)
64 (78)
38 (26)
108 (74)
0.493
13 (22)
45 (78)
18 (21)
66 (79)
25 (29)
61 (71)
0.317
Size
 ≤ 20 mm
 21–50 mm
 > 50 mm
45 (55)
32 (39)
5 (6)
99 (68)
47 (32)
0 (0)
0.004
32 (55)
24 (41)
2 (4)
55 (65)
26 (31)
3 (4)
57 (66)
29 (34)
0
0.115
Invasive Grade
 I
 II
 III
13 (16)
43 (52)
26 (32)
47 (32)
76 (52)
23 (16)
0.001
9 (16)
29 (50)
20 (34)
19 (23)
52 (62)
13 (15)
32 (37)
38 (44)
16 (19)
0.002
Lymph Node Involvement
 No
 Yes
47 (57)
35 (43)
79 (54)
67 (46)
0.671
34 (59)
24 (41)
44 (52)
40 (48)
47 (55)
39 (45)
0.699
Molecular Subtype
 Luminal A
 Luminal B
48 (59)
34 (41)
106 (73)
40 (27)
0.024
28 (48)
30 (52)
61(73)
23 (27)
65 (76)
21 (24)
0.001
Tumour Necrosis
 Low
 High
43 (52)
39 (48)
93 (64)
53 (36)
0.096
29 (50)
29 (50)
48 (57)
36 (43)
59 (69)
27 (31)
0.023
Ki67 proliferation index
 Low
 High
51 (62)
31 (38)
115 (79)
31 (21)
0.006
31 (53)
27 (47)
67 (70)
17 (30)
68 (79)
18 (21)
0.001
Lymphatic Invasion
 No
 Yes
57 (70)
25 (30)
98 (67)
48 (33)
0.711
42 (72)
16 (28)
54 (64)
30 (36)
59 (69)
27 (31)
0.587
Lymphovascular Invasion
 No
 Yes
72 (88)
10 (12)
133 (91)
13 (9)
0.428
48 (83)
10 (17)
76 (90)
8 (10)
81 (94)
5 (6)
0.029
Inflammatory Infiltrate
Klintrup Makinen Grade
 Weak
 Strong
69 (84)
13 (16)
129 (88)
17 (12)
0.367
49 (84)
9 (16)
71 (85)
13 (15)
78 (90)
8 (10)
0.244
CD68+ macrophages
 Low
 Moderate
 High
11 (13)
37 (45)
34 (42)
24 (16)
66 (45)
56 (39)
0.527
7 (12)
25 (43)
26 (45)
14 (17)
37 (44)
33 (39)
14 (16)
41 (48)
31 (36)
0.293
CD4+ T-lymphocytes
 Low
 Moderate
 High
35 (43)
22 (27)
25 (30)
73 (50)
29 (20)
44 (30)
0.420
24 (41)
18 (31)
16 (28)
40 (48)
14 (17)
30 (35)
44 (51)
19 (22)
23 (27)
0.269
CD8+ cytotoxic T-cells
 Low
 Moderate
 High
22 (27)
36 (44)
24 (29)
45 (31)
55 (37)
46 (32)
0.644
16 (28)
25 (43)
17(29)
23 (27)
33 (39)
28 (34)
28 (33)
33 (38)
25 (29)
0.635
Oncotarget7www.impactjournals.com/oncotarget
Is AR phosphorylation at Ser515 an independent 
prognostic factor for ER+ve or TNBC?
For ER+ve tumours, since pERK1/2 plus AR-515 
had significant associations with improved patient survival, 
these factors were taken into univariate and multivariate 
analysis (Table 5). On univariate analysis, size (p = 0.002), 
invasive grade (p = 0.013), lymph node involvement 
(p = 0.009), necrosis (p < 0.001), proliferation index 
(p < 0.001), lymphatic invasion (p < 0.001), cytotoxic 
t-lymphocytes (p = 0.005), TSP (p = 0.009), tumour 
budding (p = 0.001) and angiogenesis (p = 0.043) were 
significantly associated with poorer CSS. Lymphovascular 
invasion (p = 0.054) and b-lymphocytes (p = 0.064) 
trended towards significance.
On multivariate survival analysis including 
pERK1/2 plus AR-515; necrosis (p = 0.036), proliferation 
index (p = 0.014), cytotoxic t-lymphocytes (p = 0.001), 
and TSP (p = 0.033) were independent prognostic factors, 
with lymphatic invasion (p = 0.060), tumour budding 
(p = 0.084), angiogenesis (p = 0.051) and pERK1/2 
(p = 0.073) showing trends towards independence. 
However, pERK1/2 plus AR-515 does not appear to be 
independently prognostic in these patients (p = 0.682).
For TNBC, since AR-51 plus total AR had 
significant associations with poorer patient survival, these 
factors were taken into univariate and multivariate analysis 
(Table 7). On univariate analysis, size (p = 0.022), lymph 
node involvement (p < 0.001), necrosis (p = 0.030), 
lymphatic invasion (p = 0.001), lymphvascular invasion 
(p < 0.001), macrophages (p = 0.011) and cytotoxic 
t-lymphocytes (p = 0.047) were significantly associated 
with poorer CSS.  Age (p = 0.055) and plasma cells 
(p = 0.055) trended towards significance.
On multivariate survival analysis including AR-
515 plus total AR; lymph node involvement (p = 0.006), 
lymphovascular invasion (p = 0.002), and macrophages 
(p = 0.002) were independent prognostic factors. 
However, AR-515 plus total AR (p = 0.957) nor AR alone 
(p = 0.801) appear to be independently prognostic in these 
patients.
DISCUSSION
This study suggests that effects of activation 
via phosphorylation of AR at Ser515 are subtype-
dependent.  In ER+ve and HER2-type patients AR-515 
is associated with good prognosis, but in TNBC patients 
AR-515 is associated with poor prognosis.  These effects 
of AR phosphorylation appear to be associated with 
inflammation. In ER+ve tumours AR-515 was associated 
with an increase in b-lymphocytes, therefore combating 
tumour spread. In contrast, in TNBC tumours AR-515 
was associated with a decrease in macrophages, increased 
proliferation, increased tumour to stroma percentage 
and invasion. Emphasising the need for a personalised 
medicine approach, as the TNBC patients could benefit 
from anti-androgen therapy.
In the current study, AR-515 phosphorylation 
is associated with decreased Ki67 in ER+ve tumours, 
confirming previous reports that AR is a good prognostic 
factor in ER+ve breast cancer due to an anti-proliferative 
effect [27, 28].  In contrast in TNBC, AR expression is 
associated with poor prognosis, an increase in proliferation 
rate, lymphatic invasion and decreased survival [27, 29, 
30].  However, current data on the role of AR in breast 
cancer is controversial with some groups showing 
a good prognosis for AR-positive TNBC patients 
[31, 32]. Conversely, other groups have reported similar 
outcomes to the present study showing a good prognosis 
for AR/ER-positive patients and a poor prognosis for AR-
positive TNBC patients [33, 34]. However, these studies 
only considered total AR expression, with no analysis 
of AR phosphorylation and data from the current study 
CD20+ B-lymphocytes
 Low
 Moderate
 High
39 (48)
14 (17)
29 (35)
92 (63)
23 (16)
31 (21)
0.013
29 (50)
8 (14)
21 (36)
42 (50)
18 (21)
24 (29)
60 (70)
11 (13)
15 (17)
0.006
CD138+ plasma cells
 Low
 Moderate
 High
50 (61)
13 (16)
19 (23)
70 (48)
26 (18)
50 (34)
0.048
37 (64)
10 (17)
11 (19)
44 (52)
12 (14)
28 (34)
39 (45)
17 (20)
30 (35)
0.027
Tumour Stroma Percentage
 Low
 High
51 (52)
31 (38)
95 (65)
51 (35)
0.665
39 (67)
19 (33)
53 (63)
31 (37)
54 (63)
32 (37)
0.607
Tumour Budding
 Low
 High
49 (60)
33 (40)
87 (60)
59 (40)
0.980
38 (66)
20 (34)
52  (62)
32 (38)
46 (53)
40 (47)
0.135
Angiogenesis
 Low
 Moderate
 High
27 (33)
24 (29)
31 (38)
46 (32)
55 (38)
40 (30)
0.199
16 (28)
18 (31)
23 (41)
36 (43)
25 (30)
21 (27)
20 (23)
35 (41)
27 (36)
0.990
Oncotarget8www.impactjournals.com/oncotarget
Table 4: Relationship between clinico-pathological characteristics, pERK1/2 and AR-515 in  
patients with TNBC (n = 65)
AR + AR-515 pERK1/2 + AR-515
Low AR + 
AR-515  
(n = 21)
High AR or 
AR-515
(n = 27)
High AR + 
AR-515 
(n = 17)
P
Low pERK + 
AR-515
(n = 23)
High pERK 
or AR-515
(n = 32)
High pERK + 
AR-515
(n = 10)
P
Clinicopathological 
Characteristics
Age
 ≤ 50 years
 > 50 years
11 (48)
12 (52)
12 (37)
20 (63)
3 (30)
7 (70)
0.304
12 (57)
9 (43)
9 (33)
18 (67)
5 (29)
12 (71)
0.075
Size
 ≤ 20 mm
 21–50 mm
 > 50 mm
6 (26)
17 (74)
0 (0)
20 (63)
11 (34)
1 (3)
3 (30)
6 (60)
1 (10)
0.648
6 (29)
15 (71)
0 (0)
12 (44)
13 (48)
2 (8)
11 (64)
6 (36)
0 (0)
0.051
Invasive Grade
 I
 II
 III
2 (9)
3 (13)
18 (78)
1 (3)
7 (22)
24 (75)
0 (0)
2 (20)
8 (80)
0.641
1 (5)
2 (10)
18 (85)
1 (4)
6 (22)
20 (74)
1 (6)
4 (24)
12 (70)
0.353
Lymph Node Involvement
 No
 Yes
14 (62)
9 (39)
19 (59)
13 (41)
3 (30)
7 (70)
0.169
14 (66)
7 (34)
13 (48)
14 (52)
9 (53)
8 (47)
0.366
Tumour Necrosis
 Low
 High
5 (22)
18 (78)
11 (34)
21 (66)
1 (10)
9 (90)
0.806
5 (24)
16 (76)
6 (22)
21 (78)
6 (35)
11 (65)
0.452
Ki67 proliferation index
 Low
 High
17 (74)
6 (26)
27 (84)
5 (16)
8 (80)
2 (20)
0.480
17 (81)
4 (19)
22 (81)
5 (19)
13 (76)
4 (24)
0.744
Lymphatic Invasion
 No
 Yes
15 (65)
8 (35)
20 (62)
12 (38)
4 (40)
6 (60)
0.240
15 (71)
6 (29)
16  (59)
11 (41)
8 (53)
9 (47)
0.129
Lymphovascular Invasion
 No
 Yes
19 (83)
4 (17)
28 (87)
4 (13)
5 (50)
5 (50)
0.033
17 (81)
4 (19)
21 (78)
6 (22)
14 (82)
3 (18)
0.936
Inflammatory Infiltrate
Klintrup Makinen Grade
 Weak
 Strong
6 (26)
17 (74)
22 (69)
10 (31)
7 (70)
3 (30)
0.004
5 (24)
16 (76)
18 (67)
9 (33)
12 (70)
5 (30)
0.003
CD68+ macrophages
 Low
 Moderate
 High
3 (13)
8 (35)
12 (52)
10 (31)
6 (19)
16  (50)
3 (30)
5 (50)
2 (20)
0.111
2 (10)
7 (34)
12 (56)
11 (41)
5 (18)
11 (41)
3 (18)
7 (41)
7 (41)
0.093
CD4+ T-lymphocytes
 Low
 Moderate
 High
5 (22)
8 (35)
10 (43)
6 (19)
6 (19)
20 (62)
5 (50)
1 (10)
4 (40)
0.604
3 (14)
7 (34)
11 (52)
10 (37)
4 (15)
13 (48)
3 (18)
4 (24)
10 (58)
0.983
CD8+ cytotoxic T-cells
 Low
 Moderate
 High
4 (12)
8 (35)
11 (47)
7 (22)
4 (13)
21 (65)
2 (20)
6 (60)
2 (20)
0.522
4 (19)
6 (29)
12 (52)
7 (26)
7 (26)
13 (48)
3 (17)
5 (30)
9 (53)
0.726
CD20+ B-lymphocytes
 Low
 Moderate
 High
8 (35)
3 (13)
12 (52) 
9 (28)
5 (16)
18 (56)
2 (20)
2 (20)
6 (60)
0.488
7 (29)
3 (19)
12 (52)
10 (37)
6 (22)
11 (41)
3 (18)
1 (6)
13 (76)
0.231
CD138+ plasma cells
 Low
 Moderate
 High
7 (29)
2 (9)
14 (62)
11 (34)
7 (22)
14 (44)
3 (30)
1 (10)
6 (60)
0.779
6 (29)
2 (10)
13 (61)
12 (44)
4 (15)
11 (41)
3 (18)
4 (24)
10 (58)
0.302
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suggests that these opposing effects of AR may be due 
to differential phosphorylation of AR and therefore 
differential survival effects. 
To date little work has been reported on AR 
phosphorylation in breast cancer, even though this is now 
thought to be the main post-translational modification 
needed to fully activate AR [20]. One study observed 
up-regulation of AR-213 and AR-650 phosphorylation in 
invasive ductal adenocarcinoma; however patient survival 
was not investigated [35]. To our knowledge the current 
study is the first to report AR-515 phosphorylation is 
associated with poorer patient outcomes in TNBC.  This is 
in line with observations in prostate cancer where AR-515 
was associated with decreased CSS and proliferation [26]. 
ERK1/2 has been proposed to phosphorylate AR-
515 in response to EGF stimulation. Ponguta et al. used 
site directed mutagenesis within the n-terminal region of 
AR to delineate that AR-515 was the phosphorylation site 
Tumour Stroma Percentage
 Low
 High
21 (91)
2 (9)
19 (59)
13 (41)
7 (70)
3 (30)
0.033
19 (90)
2 (10)
20 (74)
7 (26)
8 (53)
9 (47)
0.003
Tumour Budding
 Low
 High
20 (87)
3 (13)
22 (69)
10 (31)
4 (40)
6 (60)
0.007
19 (90)
2 (10)
18 (67)
9 (33)
9 (53)
8 (47)
0.011
Angiogenesis
 Low
 Moderate
 High
10 (51)
4 (12)
9 (39)
10 (31)
6 (19)
16 (50)
2 (20)
3 (30)
5 (50)
0.255
9 (43)
3 (14)
9 (43)
8 (30)
7 (26)
12 (44)
5 (30)
3 (17)
9 (53)
0.413
Table 5: Univariate and multivariate survival analysis in patients with invasive ductal breast 
cancer (n = 293)
ER + ve  (n = 228) TNBC (n = 65)
Univariate HR 
(95% CI)
P Multivariate HR 
(95% CI)
P Univariate HR 
(95% CI)
P Multivariate HR 
(95% CI)
P
Clinicopathological Characteristics
Age (< 50/> 50) 1.92 (0.80–4.62) 0.143 - - 2.70 (0.98–7.44) 0.055 - -
Size (< 20/20–50/ > 50) 2.38 (1.36–4.15) 0.002 1.58 (0.67–2.89) 0.134 3.23 (1.19–7.78) 0.022 1.20 (0.42–3.40) 0.732
Invasive Grade (I/II/III) 1.83 (1.14–2.95) 0.013 1.44 (0.83–2.48) 0.193 1.38 (0.54–3.51) 0.502 - -
Lymph Node Involvement (No/Yes) 2.47 (1.25–4.88) 0.009 1.48 (0.68–3.20) 0.324 7.16 (2.38–21.5) < 0.001 5.17 (1.59-16.8) 0.006
Tumour Necrosis (Low/High) 3.19 (1.75–6.95) < 0.001 2.33 (1.06–5.14) 0.036 9.25 (1.34–69.2) 0.030 4.82 (0.57-40.5) 0.148
Ki67 proliferation index (Low/High) 3.59 (1.87–6.86) < 0.001 2.59 (1.21–5.53) 0.014 0.74 (0.22–2.53) 0.629 - -
Lymphatic Invasion (No/Yes) 3.40 (1.76–6.55) < 0.001 2.17 (0.97–4.86) 0.060 5.27 (1.91–14.5) 0.001 2.61 (0.80-8.53) 0.111
Lymphovascular Invasion (No/Yes) 2.25 (0.99–5.12) 0.054 - - 10.4 (4.13–26.0) < 0.001 6.04 (1.98-18.4) 0.002
Inflammatory Characteristics
Klintrup-Makinen Grade (Weak/Strong) 0.71 (0.25–1.99) 0.509 - - 1.04 (0.43–2.50) 0.938 - -
CD68+ macrophages (low/mod/high) 1.01 (0.64–1.60) 0.961 - - 0.49 (0.29–0.85) 0.011 0.32 (0.16–0.66) 0.002
CD4+ T-lymphocytes (low/mod/high) 0.78 (0.53–1.41) 0.199 - - 1.02 (0.60–1.75) 0.933 - -
CD8+ cytotoxic T-cells (low/mod/high) 0.54 (0.35–0.83) 0.005 0.44 (0.27–0.72) 0.001 0.58 (0.34–0.99) 0.047 0.72 (0.36–1.43) 0.346
CD20+ B-lymphocytes (low/mod/high) 0.67 (0.43–1.03) 0.064 - - 1.15 (0.69–1.90) 0.600 - -
CD138+ plasma cells (low/mod/high) 1.11 (0.77–1.60) 0.561 - - 1.76 (0.99–3.14) 0.055 - -
Tumour Stroma Percentage (low/high) 2.38 (1.25–4.54) 0.009 2.13 (1.06–4.27) 0.033 2.09 (0.85–5.12) 0.107 - -
Tumour Budding (low/high) 3.07 (1.56–6.03) 0.001 1.97 (0.91–4.26) 0.084 1.69 (0.69–4.13) 0.251 - -
Angiogenesis (low/high) 1.55 (1.01–2.37) 0.043 1.64 (1.00–2.70) 0.051 1.42 (0.84–2.42) 0.193 - -
AR Pathway
Total AR (low/high) 1.43 (0.72–2.84) 0.309 - - 3.31 (1.35–8.11) 0.006 1.14 (0.41–3.17) 0.801
AR-515 (low/high) 0.78 (0.41–1.51) 0.459 - - 1.70 (0.65–4.42) 0.274 - -
pERK1/2 (low/high) 0.43 (0.22–0.82) 0.008 0.67 (0.43–1.04) 0.073 1.33 (0.54–3.25) 0.534 - -
AR+AR-515 (low AR + AR-515/high AR or 
AR-515/high AR + AR-515)
1.04 (0.68–1.60) 0.985 - - 2.19 (1.14–4.20) 0.007 0.96 (0.26–3.58) 0.957
pERK1/2+AR-515 (low pERK + AR-515/high 
pERK or AR-515/high pERK + AR-515)
0.64 (0.42–0.98) 0.038 0.76 (0.20–2.87) 0.682 1.35 (0.77–2.34) 0.065 - -
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affected by EGF stimulation [36].  Chia et al. also showed 
that inhibition of ERK1/2 phosphorylation reduces 
expression of AR in ER-ve breast cancers.  Interestingly, 
they also showed that AR inhibition leads to down-
regulation of ERK1/2 target genes suggesting that AR 
can regulate ERK1/2 phosphorylation and kinase activity, 
creating a feedback loop [37].  In the current study, AR 
and pERK1/2 show a strong correlation and combination 
of these two proteins strengthens their individual 
effects, suggesting that ERK1/2 may be responsible for 
phosphorylation of AR-515 in these patients.
In the current study, AR-515 is present in all breast 
cancers; however the phenotypic and survival affects 
are subtype-dependent.  In ER+ve breast cancers, AR-
515 phosphorylation leads to an improved survival, this 
may be due to AR-515 increasing the rate of maturation 
of b-lymphocytes into plasma cells.  This is in contrast 
to a previous study, that suggests total AR can inhibit 
b-lymphocyte development resulting in suppression of 
systemic inflammation, however AR phosphorylation 
sites were not taken into account [38]. It is also interesting 
that in the current study only pERK1/2 was shown to 
be an independent prognostic factor in ER+ve tumours, 
suggesting it may be a driver of this pathway potentially 
via phosphorylation of AR-515.
In TNBC we observed that phosphorylation of AR-
515 leads to poorer survival possibly via down-regulation 
of inflammation. This has previously been observed in 
prostate cancer, where DHT treatment and AR activation 
was associated with decreased local inflammation, 
inflammatory growth factor production and T-lymphocyte 
proliferation [39]. This detrimental effect of AR-515 on 
inflammation and survival, suggests that anti-androgen 
therapy may be of therapeutic benefit to patients with 
TNBC. This is in line with current clinical trials were 
TNBC patients are responding to anti-androgen therapy 
[22, 40].  Currently, 30% of TNBC patients respond 
to chemotherapy, but there are no approved targeted 
treatments for the other 70%. Clinical trials are underway 
for the use of PARP inhibitors in BRCA1 mutated TNBC 
and PI3K inhibitors in PTEN mutated TNBC.  Anti-
androgens are a being trialled as potential treatment for 
AR-positive patients, which is currently around 10–15% 
TNBC patients, however using AR phosphorylation 
as a biomarker rather than total AR expression may 
increase the frequency of AR in TNBC, as even when AR 
expression is low, the receptor can still be activated via 
one of its many phosphorylation sites [20].  It has recently 
Figure 1: AR-515 is associated with poorer patient survival in triple negative breast cancer. (A) Representative 
immunohistochemical images for AR, AR-81, AR-515, pCDK1 and pERK1/2. Negative, low, moderate and high nuclear staining is shown 
for each protein.  Cytoplasmic staining can also be observed for some proteins but was not quantified as it represents the inactive form. 
(B) Kaplan-Meier curve showing that high total AR expression associates with poorer CSS in TNBC patients. (C) Kaplan-Meier curve 
showing that when total AR and AR-515 are combined, high expression of both proteins is associated with poorer CSS in TNBC patients.
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been shown that combining anti-androgens with a PI3K 
inhibitor increases their sensitivity in TNBC patients [41]. 
In conclusion, this study demonstrates 
subtype-specific differences in the effects of AR-515 
phosphorylation in breast cancer patients.  In ER+ve 
breast cancers, high phosphorylation of AR-515 conveys 
a protective effect. This is potentially due to an increased 
inflammatory response within the tumour when AR-
515 is phosphorylated.  However, in TNBC patients, 
phosphorylation of AR-515 associates with a poorer 
prognosis, possibly due to a down regulation of local 
inflammation. This difference in survival may be due to 
different substrates phosphorylating AR-515.  In ER+ve 
patients, AR-515 strongly correlates with pERK1/2, 
suggesting ERK1/2 may phosphorylate AR-515 in these 
patients. However, this is not seen in TNBC patients 
suggesting another kinase is responsible. The data 
also suggests that AR may be an important regulator 
of inflammation in breast cancer and maybe a potential 
prognostic biomarker for TNBC. It also confirms the need 
to consider phosphorylation of the AR when investigating 
activation, as differing phosphorylation sites have varied 
downstream effects. Further investigation is now needed 
to delineate how AR phosphorylation is influencing 
inflammation, is it a direct association or is another factor 
involved.  The data for TNBC also needs to be confirmed 
in a larger dataset as one limitation of this study is the low 
number of TNBC cases within the cohort.
MATERIALS AND METHODS
Patient cohort characteristics
Patients presenting with invasive ductal breast 
cancer at Glasgow Royal Infirmary, Western Infirmary and 
Stobhill Hospital between 1995 and 1998 with formalin-
fixed paraffin embedded blocks of the primary tumour 
available for evaluation were studied (n = 474). The study 
was approved by the Research Ethics Committee of the 
West Glasgow University Hospitals NHS Trust.
Clinicopathological data including age, tumour size, 
tumour grade, lymph node status, type of surgery and use of 
adjuvant treatment (chemotherapy, hormonal therapy and/
or radiotherapy) were retrieved from the routine reports. 
Tumour grade was assigned according to the Nottingham 
Grading System. ER and PR status were assessed on tissue 
microarrays (TMAs) using immunohistochemistry (IHC) 
with Dako (Glostrup, Denmark) ER antibody and Leica 
(Wetzlar, Germany) PR antibody and scored according to 
the American Society of Clinical Oncology and College 
of American Pathologists guidelines with a cut-off value 
of 1% positive tumour nuclei [42]. Her2 status were 
assessed visually using TMAs as previously described, 
that is, a score 3 þ is regarded as positive; 2 þ is regarded 
as equivocal, leading to referral for Her-2 FISH; and 0 and 
1 þ are regarded as negative [43]. 
Full-section haematoxylin and eosin (H&E) 
slides for the 474 patients were used to score local 
inflammatory infiltrate according to Klintrup-Makinen 
(KM) criteria. KM scoring of slides was carried out as 
previously described. Briefly, tumours were scored on 
four-point scores based on appearances at the tumour 
invasive margin. A score of 0 signified that there were no 
inflammatory cells at tumour’s invasive margin; score 1 
indicated a mild and patchy inflammatory cells; score 2 
denoted a prominent band-like inflammatory reaction at 
the invasive margin; and score 3 revealed a florid cup-
like inflammatory infiltrate at the invasive edge [43, 44]. 
Individual immune cell types were assessed using IHC 
staining on TMA sections for macrophages, helper and 
cytotoxic T-lymphocytes and plasma cells using CD68, 
CD4, CD8 and CD138 antibodies, respectively [45]. 
Full-section H&E slides were also used to score the 
tumour stroma percentage (TSP) as previously reported 
[46]. Briefly, at 5x magnification, an area representative of 
the tumour invasive margin was selected, and then a single 
field of 10x magnification was examined, ensuring that 
tumour cells were present at all four sides of the image 
and the area of stroma was calculated as a percentage. 
Lymphatic and blood vessel (lymphovascular) 
invasion were assessed, on 2.5-μm thick sections, using 
IHC staining with the lymphatic endothelial marker D2-
40 (Covance, Monoclonal Antibody, SIG-3730, Princeton, 
NJ, USA) diluted 1:100 and vascular endothelial marker 
Factor VIII (Mouse Monoclonal Antibody, NCL-L-
Vwf, Leica, Newcastle, UK) diluted 1:100 as previously 
described [47].  Ki67 proliferation index was assessed by 
IHC using the median as the cut-off.  Tumour budding was 
evaluated as clusters of 1-5 cancer cells within the tumour 
microenvironment.
The molecular subtypes were defined as follows: 
Luminal A: oestrogen (ER) and/or progesterone receptor 
(PR) positive, Her-2 negative or low proliferative index 
(< 15%); Luminal B: hormone receptor positive, Her-
2 positive or high proliferative index (> 15%); Her-2 
subtype: Her-2 positive and hormone receptor negative, 
any proliferative index; and triple negative: Her-2 
negative, hormone receptor negative, any proliferative 
index.
Immunohistochemistry
Antibody validation for AR-81, AR-515, pERK1/2 
and pCDK1 was carried out as previously described 
[23, 26]. Immunohistochemistry (IHC) was conducted 
in triplicate on TMAs for Cdk1 phosphorylated at Thr-
161 (pCdk1), phosphorylated ERK1/2 (pERK1/2), 
total AR and AR phosphorylated at ser-81 (AR-81), 
or ser-515 (AR-515). Slides were dewaxed in xylene 
and rehydrated through graded alcohol. For total AR, 
antigen retrieval was performed in Dako cytomation 
target retrieval solution (Dako UK Ltd.) in a pre-heated 
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water bath, 99°C, 20 min. pERK1/2 antigen retrieval 
was performed in pH9 Tris-EDTA buffer (10 mM Trizma 
Base, 0.25 mM EDTA), 96°C, 20 min. Antigen retrieval 
for remaining proteins was performed under pressure in 
Tris-EDTA buffer (5 mM Trizma Base, 1 mM EDTA, 
pH 8), 5 min. Endogenous peroxidase were blocked with 
3% H2O2. Sections were further blocked using 5% horse 
serum (10% casein for pERK1/2) in Tris-buffered saline 
(TBS). Antibodies for pCdk1 (Abcam), pERK1/2 (Cell 
Signaling Technology, USA), AR-81 (Merk Millipore, 
USA), AR-515 (Eurogentec Ltd., Southampton, UK) 
were incubated overnight at 4°C diluted in Dako antibody 
diluent at 1:150 (Dako UK Ltd.) Total AR antibody (Dako 
UK Ltd.) was incubated overnight at 4C at 1:4000. Bound 
antibody complex was visualised using EnVision plus 
kit (Dako UK Ltd.) followed by 3,3-diaminobenzidine 
tetrahydrochloride (DAB, Dako UK Ltd.). Nuclei were 
counterstained with haematoxylin and blued with Scots 
Tap Water Substitute, dehydrated through graded alcohol 
and xylene and mounted with Di-N-Butyl Phthalate in 
xylene (DPX).
TMAs were scanned using the Hamamatsu 
NanoZoomer (Welwyn Gardens City, Hertfordshire, UK) 
at × 20 magnification, and visualization was carried out 
using Slidepath Digital Image Hub, version 4.0.1 (Leica 
Biosystems, UK).  
Scoring
Only nuclear expression was scored as this 
represents the active form of each protein. Tissue staining 
intensity was scored by two blinded independent observers 
using a weighted histo-score (H-score) method [48, 49]. 
The H-score was calculated from the formula: (0 × % 
cells staining negative) + (1 × % cells staining weakly 
positive) + (2 x % cells staining moderately positive) + 
(3 × % cells staining strongly positive). The mean H-score 
from staining conducted in triplicate was used for analysis. 
Intra-class correlation coefficients (ICCCs) confirmed 
histo-scoring consistency between observers [49].
Statistical analysis
Only patients with a score for AR, AR-81 and AR-
515 were included in the analysis (n = 332). Cut-off values 
for high or low protein expression were determined by the 
median of the average values of the intensity of staining. 
The relationships between variables were assessed using 
contingency table analysis with the X2 test for linear trend. 
Correlations coefficients were analysed using a Spearman’s 
rho.  Kaplan– Meier curves with log rank analysis was 
used to examine the effect of protein expression on CSS. 
Univariate survival analysis was performed using Cox 
proportional hazards regression. Variables with P-value 
of < 0.05 were entered into a multivariable model using 
a backwards conditional method for all patients and triple 
negative patients. All statistical analyses were two-sided 
and significance defined as P-value < 0.05. All statistical 
analysis was performed using the SPSS software version 
22 (IBM SPSS, Chicago, IL, USA).  
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